The potential clinical implications of these studies suggest that selectively targeting Neu4 and Neu1 could modify the glycosylation state of cell surface proteins, thus reducing tumor growth and preventing metastatic disease. This evidence concerns the gene NEU1 and metastatic neoplasm.